Your second point about why would we release our data before the fda does their diligence on the unblinded data, supports my position. Cytodyn will review the contents of the full report with all endpoints analyzed. In parallel, the fda is already doing their analysis. If Cytodyn doesn’t get the report until , say , next week they truly won’t know what’s in the report nor the details of what the fda is seeing and hence not be in a tough situation with the SEC for not reporting a material event. My belief is the discussions are more around logistics, cost, and manufacturing with all parties believing the results will be at least promising. Per the PR at the end of 2 or 3 weeks, we will know the content of discussions and the report